WRC 0542

Drug Profile

WRC 0542

Latest Information Update: 18 Aug 2006

Price : $50

At a glance

  • Originator Aderis Pharmaceuticals (CEASED)
  • Class Neuroprotectants
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders

Most Recent Events

  • 25 Aug 1998 Preclinical development for Cardiovascular disorders in USA (Unknown route)
  • 16 May 1997 New profile
  • 16 May 1997 Preclinical development for Undefined in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top